CHEK2(CHK2)
Sign in to save this workspaceUniProt O96017 · PDB · AlphaFold · Substrate: CHKtide · Clone: full-length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Brigatinib | 99.4% | 0.6% | 82.96 | 0.513 |
| 2 | Alectinib | 98.8% | 1.2% | 95.49 | 0.651 |
| 3 | Sunitinib | 95.0% | 5.0% | 91.73 | 0.524 |
| 4 | Ponatinib | 92.6% | 7.4% | 78.23 | 0.534 |
| 5 | Bosutinib | 91.4% | 8.6% | 87.22 | 0.555 |
| 6 | Ceritinib | 88.8% | 11.2% | 95.44 | 0.618 |
| 7 | Selpercatinib | 86.3% | 13.7% | 96.72 | 0.635 |
| 8 | Netarsudil | 86.0% | 14.0% | 93.22 | 0.676 |
| 9 | Gilteritinib | 82.5% | 17.5% | 88.97 | 0.506 |
| 10 | Neratinib | 76.1% | 23.9% | 93.18 | 0.597 |
| 11 | Vandetanib | 58.3% | 41.7% | 95.74 | 0.723 |
| 12 | Fedratinib | 50.0% | 50.0% | 96.21 | 0.576 |
| 13 | Cabozantinib | 43.3% | 56.7% | 92.73 | 0.751 |
| 14 | Defactinib | 38.9% | 61.1% | 92.68 | 0.450 |
| 15 | Lazertinib | 35.3% | 64.7% | 97.47 | 0.674 |
| 16 | Lorlatinib | 34.3% | 65.7% | 97.24 | 0.694 |
| 17 | Tivozanib | 32.8% | 67.2% | 92.42 | 0.673 |
| 18 | Afatinib | 31.6% | 68.4% | 98.50 | 0.709 |
| 19 | Gefitinib | 30.7% | 69.3% | 99.25 | 0.650 |
| 20 | Capivasertib | 30.4% | 69.6% | 96.48 | 0.644 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 3.87
- Epithelial log2(TPM+1): 4.38
- Fold change: -0.50
- Status: No significant change
Selectivity landscape vs inhibition on CHEK2
Each point is one of the 92 approved drugs; color = inhibition % on CHEK2.
Variants (1)
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…